Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Adaptimmune Therapeutics's Revenue for the
three
months ended in Jun. 2025 was $13.68 Mil. Adaptimmune Therapeutics's average Accounts Receivable for the
three
months ended in Jun. 2025 was $6.85 Mil.
Hence, Adaptimmune Therapeutics's Receivables Turnover for the
three
months ended in Jun. 2025 was 2.00.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Adaptimmune Therapeutics Receivables Turnover Related Terms
Adaptimmune Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Adaptimmune Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADAPY vs BCLI, APRE, JSPR: Receivables Turnover Comparison
For the Biotechnology subindustry, Adaptimmune Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptimmune Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Adaptimmune Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptimmune Therapeutics (ADAPY) has a Receivables Turnover of 2.00 as of Jun. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Receivables Turnover too high?
Adaptimmune Therapeutics' current Receivables Turnover is 2.00. The Biotechnology industry median Receivables Turnover is 5.28. Adaptimmune Therapeutics' value of 2.00 is 62.1% below this industry median.
How does Adaptimmune Therapeutics' Receivables Turnover compare to BCLI and APRE?
Adaptimmune Therapeutics' Receivables Turnover of 2.00 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.28. Adaptimmune Therapeutics' value of 2.00 is 62.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adaptimmune Therapeutics's current Receivables Turnover of 2.00 is 62.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Adaptimmune Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptimmune Therapeutics's current Receivables Turnover is 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Receivables Turnover of 2.00. The current Receivables Turnover is 2.00 and 62.1% below the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Receivables Turnover is 2.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADAPY has been successfully added to your 
